Panama Investigates CK Hutchison’s Port Unit After Court Voids Canal Contracts 
Australia Housing Market Hits Record High Despite RBA Rate Hike 
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
Gold Prices Steady in Asia, Set for Strong February Gains on Safe-Haven Demand 
Argentina Tax Reform 2026: President Javier Milei Pushes Lower Taxes and Structural Changes 
FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
Lynas Rare Earths Shares Surge 7% After Malaysia Renews Processing Plant Licence for 10 Years 
Hyundai Motor Group to Invest $6.26 Billion in AI Data Center, Robotics and Renewable Energy Projects in South Korea 
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute 
Australia Targets AI Platforms With Strict Age Verification Rules 
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge 
Strait of Hormuz LNG Crisis Triggers Global Energy Market Shock 
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
Greg Abel’s First Berkshire Hathaway Shareholder Letter Signals Continuity, Caution, and Capital Discipline 
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade 
Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom 
Pfizer announced on Wednesday, April 28, that it has acquired Amplyx Pharmaceuticals. The company stated that the purchase would bolster its portfolio as it offers the opportunity to strengthen “Pfizer’s expertise and deep heritage in infectious disease.”
As per Reuters, Amplyx Pharmaceuticals is based in San Diego, and it is developing new treatments against drug-resistant microbes in patients with compromised immune systems.
The anti-fungal drug has been named fosmanogepix, and it is now in the second phase of clinical trials.
Pfizer to continue testing on Amplyx’s experimental drug
The New York-headquartered multinational pharmaceutical company acquired Amplyx while it is in the middle of conducting trials for its anti-fungal drug that is hoped to effectively fight off drug-resistant infections that ravage the immune system of patients. Since this is the case, Pfizer will not abandon but continue the clinical trials of this experimental drug.
If Amplyx's fosmanogepix drug will show good results and eventually be approved, it will become the first type of new antifungal treatment to come in the last 20 years. This is an important drug because it can kill fungi, like bacteria, that have turned resistant to common drugs or medicines.
Why Pfizer is further expanding its infectious disease folio
It was estimated that if this kind of drug will not be developed, drug-resistant superbugs may possibly kill at least 10 million people by 2050. This is why Pfizer has been expanding its portfolio for treatments that can fight these threatening superbugs.
Pfizer noted that hospitalized patients’ immune systems tend to become weaker since the drugs they take do not work, and this has become a problem not just for the ill but for doctors as well. This scenario just showed how much people need effective anti-fungal treatments for such patients.
“The COVID-19 pandemic has been a stark reminder of the devastating impact of infectious diseases, highlighting the continuous need for new anti-infective therapies to treat both emerging and difficult to treat bacterial, viral and fungal infections,” Pfizer Hospital’s global president, Angela Lukin, said in a press release. “We are deeply committed to helping patients suffering from infectious diseases, continuously seeking opportunities to build our portfolio of anti-infective therapies.”
